Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
A Serotonin 2A-Receptor Decoy Peptide Potently Lowers Blood Pressure in Male Zucker Diabetic, Fatty, Hypertensive Rats.

Endocrinology, diabetes and metabolism journal

Zimering MB.
PMID: 35035793
Endocrinol Diabetes Metab J. 2021 Aug;5(2). doi: 10.31038/edmj.2021523. Epub 2021 Aug 30.

AIMS: To test whether a novel 5-hydroxytryptamine 2A decoy receptor peptide, SN..8 (Sertuercept), administered via intraperitoneal injection, acutely lowers arterial blood pressure in obese, hypertensive male Zucker diabetic rats (ZDF). To examine the safety, tolerability and possible reno-protective effects...

Cite
Zimering MB. A Serotonin 2A-Receptor Decoy Peptide Potently Lowers Blood Pressure in Male Zucker Diabetic, Fatty, Hypertensive Rats. Endocrinol Diabetes Metab J. 2021;5(2)doi: 10.31038/edmj.2021523.
Zimering, M. B. (2021). A Serotonin 2A-Receptor Decoy Peptide Potently Lowers Blood Pressure in Male Zucker Diabetic, Fatty, Hypertensive Rats. Endocrinology, diabetes and metabolism journal, 5(2), . https://doi.org/10.31038/edmj.2021523
Zimering, Mark B. "A Serotonin 2A-Receptor Decoy Peptide Potently Lowers Blood Pressure in Male Zucker Diabetic, Fatty, Hypertensive Rats." Endocrinology, diabetes and metabolism journal vol. 5,2 (2021). doi: https://doi.org/10.31038/edmj.2021523
Zimering MB. A Serotonin 2A-Receptor Decoy Peptide Potently Lowers Blood Pressure in Male Zucker Diabetic, Fatty, Hypertensive Rats. Endocrinol Diabetes Metab J. 2021 Aug;5(2). doi: 10.31038/edmj.2021523. Epub 2021 Aug 30. PMID: 35035793; PMCID: PMC8759716.
Copy Download .nbib Format: NLM
A Serotonin 2A-Receptor Decoy Peptide Potently Lowers Blood Pressure in Male Zucker Diabetic, Fatty, Hypertensive Rats.

Endocrinology, diabetes and metabolism journal

Zimering MB.
PMID: 35035793
Endocrinol Diabetes Metab J. 2021 Aug;5(2). doi: 10.31038/edmj.2021523. Epub 2021 Aug 30.

AIMS: To test whether a novel 5-hydroxytryptamine 2A decoy receptor peptide, SN..8 (Sertuercept), administered via intraperitoneal injection, acutely lowers arterial blood pressure in obese, hypertensive male Zucker diabetic rats (ZDF). To examine the safety, tolerability and possible reno-protective effects...

Cite
Zimering MB. A Serotonin 2A-Receptor Decoy Peptide Potently Lowers Blood Pressure in Male Zucker Diabetic, Fatty, Hypertensive Rats. Endocrinol Diabetes Metab J. 2021;5(2)doi: 10.31038/edmj.2021523.
Zimering, M. B. (2021). A Serotonin 2A-Receptor Decoy Peptide Potently Lowers Blood Pressure in Male Zucker Diabetic, Fatty, Hypertensive Rats. Endocrinology, diabetes and metabolism journal, 5(2), . https://doi.org/10.31038/edmj.2021523
Zimering, Mark B. "A Serotonin 2A-Receptor Decoy Peptide Potently Lowers Blood Pressure in Male Zucker Diabetic, Fatty, Hypertensive Rats." Endocrinology, diabetes and metabolism journal vol. 5,2 (2021). doi: https://doi.org/10.31038/edmj.2021523
Zimering MB. A Serotonin 2A-Receptor Decoy Peptide Potently Lowers Blood Pressure in Male Zucker Diabetic, Fatty, Hypertensive Rats. Endocrinol Diabetes Metab J. 2021 Aug;5(2). doi: 10.31038/edmj.2021523. Epub 2021 Aug 30. PMID: 35035793; PMCID: PMC8759716.
Copy Download .nbib Format: NLM
Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy.

Endocrinology, diabetes and metabolism journal

Zimering MB, Shin JJ, Zaitz JD, Nunez EA, Gianoukakis AG.
PMID: 30854171
Endocrinol Diabetes Metab J. 2019 Feb;3(1). Epub 2019 Jan 08.

PURPOSE: To report a case of orbital fat expansion leading to globe prolapse in a Graves' disease patient undergoing high-dose glucocorticoid therapy. To evaluate the growth factor receptor specificities of plasma autoantibodies in Graves' disease patients who exhibited contrasting...

Cite
Zimering MB, Shin JJ, Zaitz JD, et al. Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy. Endocrinol Diabetes Metab J. 2019;3(1)
Zimering, M. B., Shin, J. J., Zaitz, J. D., Nunez, E. A., & Gianoukakis, A. G. (2019). Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy. Endocrinology, diabetes and metabolism journal, 3(1), .
Zimering, Mark B, et al. "Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy." Endocrinology, diabetes and metabolism journal vol. 3,1 (2019).
Zimering MB, Shin JJ, Zaitz JD, Nunez EA, Gianoukakis AG. Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy. Endocrinol Diabetes Metab J. 2019 Feb;3(1). Epub 2019 Jan 08. PMID: 30854171; PMCID: PMC6407713.
Copy Download .nbib Format: NLM
The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider.

Endocrinology, diabetes and metabolism journal

Cherukuri L, Smith MS, Tayek JA.
PMID: 30370022
Endocrinol Diabetes Metab J. 2018 Sep;2(3). Epub 2018 Jul 08.

INTRODUCTION: Cost of generic medications has risen more in the past few years than any other time in history. While medical insurance covers much of these costs, health care professionals can better provide medications that have the longest duration...

Cite
Cherukuri L, Smith MS, Tayek JA. The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider. Endocrinol Diabetes Metab J. 2018;2(3)
Cherukuri, L., Smith, M. S., & Tayek, J. A. (2018). The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider. Endocrinology, diabetes and metabolism journal, 2(3), .
Cherukuri, Lavanya, et al. "The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider." Endocrinology, diabetes and metabolism journal vol. 2,3 (2018).
Cherukuri L, Smith MS, Tayek JA. The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider. Endocrinol Diabetes Metab J. 2018 Sep;2(3). Epub 2018 Jul 08. PMID: 30370022; PMCID: PMC6200420.
Copy Download .nbib Format: NLM
Adipose and Liver Function in Primate Offspring with Insulin Resistance Induced by Estrogen Deprivation in Utero.

Endocrinology, diabetes and metabolism journal

Kim SO, Aberdeen G, Lynch TJ, Albrecht ED, Pepe GJ.
PMID: 29983904
Endocrinol Diabetes Metab J. 2017 Aug;1(3). Epub 2017 Sep 12.

PURPOSE: We recently demonstrated that offspring delivered to baboons deprived of estrogen during the second half of gestation exhibited insulin resistance. Therefore, because skeletal muscle accounts for >80% of insulin dependent glucose disposal, we suggested that estrogen RESULTS: The...

Cite
Kim SO, Aberdeen G, Lynch TJ, et al. Adipose and Liver Function in Primate Offspring with Insulin Resistance Induced by Estrogen Deprivation in Utero. Endocrinol Diabetes Metab J. 2017;1(3)
Kim, S. O., Aberdeen, G., Lynch, T. J., Albrecht, E. D., & Pepe, G. J. (2017). Adipose and Liver Function in Primate Offspring with Insulin Resistance Induced by Estrogen Deprivation in Utero. Endocrinology, diabetes and metabolism journal, 1(3), .
Kim, Soon Ok, et al. "Adipose and Liver Function in Primate Offspring with Insulin Resistance Induced by Estrogen Deprivation in Utero." Endocrinology, diabetes and metabolism journal vol. 1,3 (2017).
Kim SO, Aberdeen G, Lynch TJ, Albrecht ED, Pepe GJ. Adipose and Liver Function in Primate Offspring with Insulin Resistance Induced by Estrogen Deprivation in Utero. Endocrinol Diabetes Metab J. 2017 Aug;1(3). Epub 2017 Sep 12. PMID: 29983904; PMCID: PMC6035008.
Copy Download .nbib Format: NLM
Circulating Agonist Autoantibody to 5-Hydroxytryptamine 2A Receptor in Lean and Diabetic Fatty Zucker Rat Strains.

Endocrinology, diabetes and metabolism journal

Zimering MB, Grinberg M, Burton J, Pang K.
PMID: 33052255
Endocrinol Diabetes Metab J. 2020 Aug;4(3). Epub 2020 Aug 28.

AIMS: Circulating neurotoxic autoantibodies to the 5-hydroxytryptamine 2A receptor were increased in older adult type 2 diabetes in association with certain neurodegenerative complications. The male Zucker diabetic fatty (ZDF) rat is a model system for studies of obese, type...

Cite
Zimering MB, Grinberg M, Burton J, et al. Circulating Agonist Autoantibody to 5-Hydroxytryptamine 2A Receptor in Lean and Diabetic Fatty Zucker Rat Strains. Endocrinol Diabetes Metab J. 2020;4(3)
Zimering, M. B., Grinberg, M., Burton, J., & Pang, K. (2020). Circulating Agonist Autoantibody to 5-Hydroxytryptamine 2A Receptor in Lean and Diabetic Fatty Zucker Rat Strains. Endocrinology, diabetes and metabolism journal, 4(3), .
Zimering, M B, et al. "Circulating Agonist Autoantibody to 5-Hydroxytryptamine 2A Receptor in Lean and Diabetic Fatty Zucker Rat Strains." Endocrinology, diabetes and metabolism journal vol. 4,3 (2020).
Zimering MB, Grinberg M, Burton J, Pang K. Circulating Agonist Autoantibody to 5-Hydroxytryptamine 2A Receptor in Lean and Diabetic Fatty Zucker Rat Strains. Endocrinol Diabetes Metab J. 2020 Aug;4(3). Epub 2020 Aug 28. PMID: 33052255; PMCID: PMC7550200.
Copy Download .nbib Format: NLM
Autoantibodies in Type-2 Diabetes having Neurovascular Complications Bind to the Second Extracellular Loop of the 5-Hydroxytryptamine 2A Receptor.

Endocrinology, diabetes and metabolism journal

Zimering MB.
PMID: 31565198
Endocrinol Diabetes Metab J. 2019 Aug;3(4). Epub 2019 Aug 14.

No abstract available.

Cite
Zimering MB. Autoantibodies in Type-2 Diabetes having Neurovascular Complications Bind to the Second Extracellular Loop of the 5-Hydroxytryptamine 2A Receptor. Endocrinol Diabetes Metab J. 2019;3(4)
Zimering, M. B. (2019). Autoantibodies in Type-2 Diabetes having Neurovascular Complications Bind to the Second Extracellular Loop of the 5-Hydroxytryptamine 2A Receptor. Endocrinology, diabetes and metabolism journal, 3(4), .
Zimering, Mark B. "Autoantibodies in Type-2 Diabetes having Neurovascular Complications Bind to the Second Extracellular Loop of the 5-Hydroxytryptamine 2A Receptor." Endocrinology, diabetes and metabolism journal vol. 3,4 (2019).
Zimering MB. Autoantibodies in Type-2 Diabetes having Neurovascular Complications Bind to the Second Extracellular Loop of the 5-Hydroxytryptamine 2A Receptor. Endocrinol Diabetes Metab J. 2019 Aug;3(4). Epub 2019 Aug 14. PMID: 31565198; PMCID: PMC6764514.
Copy Download .nbib Format: NLM
Schizophrenia Plasma Autoantibodies Promote 'Biased Agonism' at the 5-Hydroxytryptamine 2A Receptor: Neurotoxicity is Positively Modulated by Metabotropic Glutamate 2/3 Receptor Agonism.

Endocrinology, diabetes and metabolism journal

Zimering MB, Nadkarni SG.
PMID: 31537990
Endocrinol Diabetes Metab J. 2019;3(4). Epub 2019 Aug 14.

AIMS: To test whether neurite-inhibitory plasma autoantibodies in chronic schizophrenia activate Gq/11- and Gi- coupled signaling pathways downstream of 5-hydroxytryptamine 2A receptor activation; and for modulation of serotonergic signaling by the metabotropic 2/3 receptor agonist LY379268.METHODS: Plasma from five...

Cite
Zimering MB, Nadkarni SG. Schizophrenia Plasma Autoantibodies Promote 'Biased Agonism' at the 5-Hydroxytryptamine 2A Receptor: Neurotoxicity is Positively Modulated by Metabotropic Glutamate 2/3 Receptor Agonism. Endocrinol Diabetes Metab J. 2019;3(4)
Zimering, M. B., & Nadkarni, S. G. (2019). Schizophrenia Plasma Autoantibodies Promote 'Biased Agonism' at the 5-Hydroxytryptamine 2A Receptor: Neurotoxicity is Positively Modulated by Metabotropic Glutamate 2/3 Receptor Agonism. Endocrinology, diabetes and metabolism journal, 3(4), .
Zimering, Mark B, and Nadkarni, Shree G. "Schizophrenia Plasma Autoantibodies Promote 'Biased Agonism' at the 5-Hydroxytryptamine 2A Receptor: Neurotoxicity is Positively Modulated by Metabotropic Glutamate 2/3 Receptor Agonism." Endocrinology, diabetes and metabolism journal vol. 3,4 (2019).
Zimering MB, Nadkarni SG. Schizophrenia Plasma Autoantibodies Promote 'Biased Agonism' at the 5-Hydroxytryptamine 2A Receptor: Neurotoxicity is Positively Modulated by Metabotropic Glutamate 2/3 Receptor Agonism. Endocrinol Diabetes Metab J. 2019;3(4). Epub 2019 Aug 14. PMID: 31537990; PMCID: PMC6751558.
Copy Download .nbib Format: NLM
Inverse Association between Serotonin 2A Receptor Antagonist Medication Use and Mortality in Severe COVID-19 Infection.

Endocrinology, diabetes and metabolism journal

Zimering MB, Razzaki T, Tsang T, Shin JJ.
PMID: 33117497
Endocrinol Diabetes Metab J. 2020 Sep 15;4(4):1-5.

Advanced age and medical co-morbidity are strong predictors of mortality in COVID-19 infection. Yet few studies (to date) have specifically addressed risk factors associated with COVID-19 mortality in a high-risk subgroup of older US adults having one or more...

Cite
Zimering MB, Razzaki T, Tsang T, et al. Inverse Association between Serotonin 2A Receptor Antagonist Medication Use and Mortality in Severe COVID-19 Infection. Endocrinol Diabetes Metab J. 2020;4(4):1-5
Zimering, M. B., Razzaki, T., Tsang, T., & Shin, J. J. (2020). Inverse Association between Serotonin 2A Receptor Antagonist Medication Use and Mortality in Severe COVID-19 Infection. Endocrinology, diabetes and metabolism journal, 4(4), 1-5.
Zimering, Mark B, et al. "Inverse Association between Serotonin 2A Receptor Antagonist Medication Use and Mortality in Severe COVID-19 Infection." Endocrinology, diabetes and metabolism journal vol. 4,4 (2020): 1-5.
Zimering MB, Razzaki T, Tsang T, Shin JJ. Inverse Association between Serotonin 2A Receptor Antagonist Medication Use and Mortality in Severe COVID-19 Infection. Endocrinol Diabetes Metab J. 2020 Sep 15;4(4):1-5. PMID: 33117497; PMCID: PMC7590925.
Copy Download .nbib Format: NLM
Schizophrenia Plasma Autoantibodies Promote 'Biased Agonism' at the 5-Hydroxytryptamine 2A Receptor: Neurotoxicity is Positively Modulated by Metabotropic Glutamate 2/3 Receptor Agonism.

Endocrinology, diabetes and metabolism journal

Zimering MB, Nadkarni SG.
PMID: 31537990
Endocrinol Diabetes Metab J. 2019;3(4). Epub 2019 Aug 14.

AIMS: To test whether neurite-inhibitory plasma autoantibodies in chronic schizophrenia activate Gq/11- and Gi- coupled signaling pathways downstream of 5-hydroxytryptamine 2A receptor activation; and for modulation of serotonergic signaling by the metabotropic 2/3 receptor agonist LY379268.METHODS: Plasma from five...

Cite
Zimering MB, Nadkarni SG. Schizophrenia Plasma Autoantibodies Promote 'Biased Agonism' at the 5-Hydroxytryptamine 2A Receptor: Neurotoxicity is Positively Modulated by Metabotropic Glutamate 2/3 Receptor Agonism. Endocrinol Diabetes Metab J. 2019;3(4)
Zimering, M. B., & Nadkarni, S. G. (2019). Schizophrenia Plasma Autoantibodies Promote 'Biased Agonism' at the 5-Hydroxytryptamine 2A Receptor: Neurotoxicity is Positively Modulated by Metabotropic Glutamate 2/3 Receptor Agonism. Endocrinology, diabetes and metabolism journal, 3(4), .
Zimering, Mark B, and Nadkarni, Shree G. "Schizophrenia Plasma Autoantibodies Promote 'Biased Agonism' at the 5-Hydroxytryptamine 2A Receptor: Neurotoxicity is Positively Modulated by Metabotropic Glutamate 2/3 Receptor Agonism." Endocrinology, diabetes and metabolism journal vol. 3,4 (2019).
Zimering MB, Nadkarni SG. Schizophrenia Plasma Autoantibodies Promote 'Biased Agonism' at the 5-Hydroxytryptamine 2A Receptor: Neurotoxicity is Positively Modulated by Metabotropic Glutamate 2/3 Receptor Agonism. Endocrinol Diabetes Metab J. 2019;3(4). Epub 2019 Aug 14. PMID: 31537990; PMCID: PMC6751558.
Copy Download .nbib Format: NLM
Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy.

Endocrinology, diabetes and metabolism journal

Zimering MB, Shin JJ, Zaitz JD, Nunez EA, Gianoukakis AG.
PMID: 30854171
Endocrinol Diabetes Metab J. 2019 Feb;3(1). Epub 2019 Jan 08.

PURPOSE: To report a case of orbital fat expansion leading to globe prolapse in a Graves' disease patient undergoing high-dose glucocorticoid therapy. To evaluate the growth factor receptor specificities of plasma autoantibodies in Graves' disease patients who exhibited contrasting...

Cite
Zimering MB, Shin JJ, Zaitz JD, et al. Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy. Endocrinol Diabetes Metab J. 2019;3(1)
Zimering, M. B., Shin, J. J., Zaitz, J. D., Nunez, E. A., & Gianoukakis, A. G. (2019). Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy. Endocrinology, diabetes and metabolism journal, 3(1), .
Zimering, Mark B, et al. "Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy." Endocrinology, diabetes and metabolism journal vol. 3,1 (2019).
Zimering MB, Shin JJ, Zaitz JD, Nunez EA, Gianoukakis AG. Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy. Endocrinol Diabetes Metab J. 2019 Feb;3(1). Epub 2019 Jan 08. PMID: 30854171; PMCID: PMC6407713.
Copy Download .nbib Format: NLM
Autoantibodies in Type-2 Diabetes having Neurovascular Complications Bind to the Second Extracellular Loop of the 5-Hydroxytryptamine 2A Receptor.

Endocrinology, diabetes and metabolism journal

Zimering MB.
PMID: 31565198
Endocrinol Diabetes Metab J. 2019 Aug;3(4). Epub 2019 Aug 14.

No abstract available.

Cite
Zimering MB. Autoantibodies in Type-2 Diabetes having Neurovascular Complications Bind to the Second Extracellular Loop of the 5-Hydroxytryptamine 2A Receptor. Endocrinol Diabetes Metab J. 2019;3(4)
Zimering, M. B. (2019). Autoantibodies in Type-2 Diabetes having Neurovascular Complications Bind to the Second Extracellular Loop of the 5-Hydroxytryptamine 2A Receptor. Endocrinology, diabetes and metabolism journal, 3(4), .
Zimering, Mark B. "Autoantibodies in Type-2 Diabetes having Neurovascular Complications Bind to the Second Extracellular Loop of the 5-Hydroxytryptamine 2A Receptor." Endocrinology, diabetes and metabolism journal vol. 3,4 (2019).
Zimering MB. Autoantibodies in Type-2 Diabetes having Neurovascular Complications Bind to the Second Extracellular Loop of the 5-Hydroxytryptamine 2A Receptor. Endocrinol Diabetes Metab J. 2019 Aug;3(4). Epub 2019 Aug 14. PMID: 31565198; PMCID: PMC6764514.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries